Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 508

1.

Second-line rescue triple therapy with levofloxacin after failure of non-bismuth quadruple "sequential" or "concomitant" treatment to eradicate H. pylori infection.

Gisbert JP, Molina-Infante J, Marin AC, Vinagre G, Barrio J, McNicholl AG.

Scand J Gastroenterol. 2013 Jun;48(6):652-6. doi: 10.3109/00365521.2013.786132. Epub 2013 Apr 5.

PMID:
23556551
2.

Third-line rescue therapy with bismuth-containing quadruple regimen after failure of two treatments (with clarithromycin and levofloxacin) for H. pylori infection.

Gisbert JP, Perez-Aisa A, Rodrigo L, Molina-Infante J, Modolell I, Bermejo F, Castro-Fernández M, Antón R, Sacristán B, Cosme A, Barrio J, Harb Y, Gonzalez-Barcenas M, Fernandez-Bermejo M, Algaba A, Marín AC, McNicholl AG; H. pylori Study Group of the Spanish Gastroenterology Association.

Dig Dis Sci. 2014 Feb;59(2):383-9. doi: 10.1007/s10620-013-2900-x. Epub 2013 Oct 15.

PMID:
24126798
3.

Helicobacter pylori second-line rescue therapy with levofloxacin- and bismuth-containing quadruple therapy, after failure of standard triple or non-bismuth quadruple treatments.

Gisbert JP, Romano M, Gravina AG, Solís-Muñoz P, Bermejo F, Molina-Infante J, Castro-Fernández M, Ortuño J, Lucendo AJ, Herranz M, Modolell I, Del Castillo F, Gómez J, Barrio J, Velayos B, Gómez B, Domínguez JL, Miranda A, Martorano M, Algaba A, Pabón M, Angueira T, Fernández-Salazar L, Federico A, Marín AC, McNicholl AG.

Aliment Pharmacol Ther. 2015 Apr;41(8):768-75. doi: 10.1111/apt.13128. Epub 2015 Feb 23.

4.

Second-line rescue therapy with levofloxacin after H. pylori treatment failure: a Spanish multicenter study of 300 patients.

Gisbert JP, Bermejo F, Castro-Fernández M, Pérez-Aisa A, Fernández-Bermejo M, Tomas A, Barrio J, Bory F, Almela P, Sánchez-Pobre P, Cosme A, Ortiz V, Niño P, Khorrami S, Benito LM, Carneros JA, Lamas E, Modolell I, Franco A, Ortuño J, Rodrigo L, García-Durán F, O'Callaghan E, Ponce J, Valer MP, Calvet X; H. pylori Study Group of the Asociación Española de Gastroenterología.

Am J Gastroenterol. 2008 Jan;103(1):71-6. Epub 2007 Aug 31.

PMID:
17764498
5.

Second-line therapy with levofloxacin after failure of treatment to eradicate helicobacter pylori infection: time trends in a Spanish Multicenter Study of 1000 patients.

Gisbert JP, Pérez-Aisa A, Bermejo F, Castro-Fernández M, Almela P, Barrio J, Cosme A, Modolell I, Bory F, Fernández-Bermejo M, Rodrigo L, Ortuño J, Sánchez-Pobre P, Khorrami S, Franco A, Tomas A, Guerra I, Lamas E, Ponce J, Calvet X; H. pylori Study Group of the Asociación Española de Gastroenterología (Spanish Gastroenterology Association).

J Clin Gastroenterol. 2013 Feb;47(2):130-5. doi: 10.1097/MCG.0b013e318254ebdd.

PMID:
22647827
6.

Helicobacter pylori first-line and rescue treatments in the presence of penicillin allergy.

Gisbert JP, Barrio J, Modolell I, Molina-Infante J, Aisa AP, Castro-Fernández M, Rodrigo L, Cosme A, Gisbert JL, Fernández-Bermejo M, Marcos S, Marín AC, McNicholl AG.

Dig Dis Sci. 2015 Feb;60(2):458-64. doi: 10.1007/s10620-014-3365-2. Epub 2014 Sep 19.

PMID:
25236423
7.

Two-week, high-dose proton pump inhibitor, moxifloxacin triple Helicobacter pylori therapy after failure of standard triple or non-bismuth quadruple treatments.

Gisbert JP, Romano M, Molina-Infante J, Lucendo AJ, Medina E, Modolell I, Rodríguez-Tellez M, Gomez B, Barrio J, Perona M, Ortuño J, Ariño I, Domínguez-Muñoz JE, Perez-Aisa Á, Bermejo F, Domínguez JL, Almela P, Gomez-Camarero J, Millastre J, Martin-Noguerol E, Gravina AG, Martorano M, Miranda A, Federico A, Fernandez-Bermejo M, Angueira T, Ferrer-Barcelo L, Fernández N, Marín AC, McNicholl AG.

Dig Liver Dis. 2015 Feb;47(2):108-13. doi: 10.1016/j.dld.2014.10.009. Epub 2014 Nov 11.

PMID:
25454706
8.

Third-line rescue therapy with levofloxacin after two H. pylori treatment failures.

Gisbert JP, Castro-Fernández M, Bermejo F, Pérez-Aisa A, Ducons J, Fernández-Bermejo M, Bory F, Cosme A, Benito LM, López-Rivas L, Lamas E, Pabón M, Olivares D; H. pylori Study Group of the Asociación Española de Gastroenterología.

Am J Gastroenterol. 2006 Feb;101(2):243-7.

PMID:
16454825
9.

Fourth-line rescue therapy with rifabutin in patients with three Helicobacter pylori eradication failures.

Gisbert JP, Castro-Fernandez M, Perez-Aisa A, Cosme A, Molina-Infante J, Rodrigo L, Modolell I, Cabriada JL, Gisbert JL, Lamas E, Marcos E, Calvet X.

Aliment Pharmacol Ther. 2012 Apr;35(8):941-7. doi: 10.1111/j.1365-2036.2012.05053.x. Epub 2012 Feb 28.

10.

Ten-day Quadruple therapy comprising proton-pump inhibitor, bismuth, tetracycline, and levofloxacin achieves a high eradication rate for Helicobacter pylori infection after failure of sequential therapy.

Hsu PI, Chen WC, Tsay FW, Shih CA, Kao SS, Wang HM, Yu HC, Lai KH, Tseng HH, Peng NJ, Chen A, Kuo CH, Wu DC; Taiwan Acid-Related Disease (TARD) Study Group.

Helicobacter. 2014 Feb;19(1):74-9. doi: 10.1111/hel.12085. Epub 2013 Sep 6.

PMID:
24033865
11.

Nonbismuth quadruple (concomitant) therapy: empirical and tailored efficacy versus standard triple therapy for clarithromycin-susceptible Helicobacter pylori and versus sequential therapy for clarithromycin-resistant strains.

Molina-Infante J, Pazos-Pacheco C, Vinagre-Rodriguez G, Perez-Gallardo B, Dueñas-Sadornil C, Hernandez-Alonso M, Gonzalez-Garcia G, Mateos-Rodriguez JM, Fernandez-Bermejo M, Gisbert JP.

Helicobacter. 2012 Aug;17(4):269-76. doi: 10.1111/j.1523-5378.2012.00947.x. Epub 2012 Mar 30.

PMID:
22759326
12.

Concomitant therapy achieved the best eradication rate for Helicobacter pylori among various treatment strategies.

Lee HJ, Kim JI, Lee JS, Jun EJ, Oh JH, Cheung DY, Chung WC, Kim BW, Kim SS.

World J Gastroenterol. 2015 Jan 7;21(1):351-9. doi: 10.3748/wjg.v21.i1.351.

13.

Review article: non-bismuth quadruple (concomitant) therapy for eradication of Helicobater pylori.

Gisbert JP, Calvet X.

Aliment Pharmacol Ther. 2011 Sep;34(6):604-17. doi: 10.1111/j.1365-2036.2011.04770.x. Epub 2011 Jul 11. Review.

14.

Triple therapy with high-dose proton-pump inhibitor, amoxicillin, and doxycycline is useless for Helicobacter pylori eradication: a proof-of-concept study.

Almeida N, Romãozinho JM, Donato MM, Luxo C, Cardoso O, Cipriano MA, Marinho C, Sofia C.

Helicobacter. 2014 Apr;19(2):90-7. doi: 10.1111/hel.12106. Epub 2014 Feb 10.

PMID:
24506175
15.

Comparison of sequential and standard triple-drug regimen for Helicobacter pylori eradication: a 14-day, open-label, randomized, prospective, parallel-arm study in adult patients with nonulcer dyspepsia.

Uygun A, Kadayifci A, Yesilova Z, Safali M, Ilgan S, Karaeren N.

Clin Ther. 2008 Mar;30(3):528-34. doi: 10.1016/j.clinthera.2008.03.009.

PMID:
18405790
16.

Ranitidine bismuth citrate-based triple therapies as a second-line therapy for Helicobacter pylori in Turkish patients.

Köksal AS, Parlak E, Filik L, Yolcu OF, Odemiş B, Ulker A, Saşmaz N, Ozden A, Sahin B.

J Gastroenterol Hepatol. 2005 Apr;20(4):637-42.

PMID:
15836716
17.
18.

Levofloxacin, bismuth, amoxicillin and esomeprazole as second-line Helicobacter pylori therapy after failure of non-bismuth quadruple therapy.

Song Z, Zhou L, Zhang J, He L, Bai P, Xue Y.

Dig Liver Dis. 2016 May;48(5):506-11. doi: 10.1016/j.dld.2016.01.002. Epub 2016 Jan 15.

PMID:
26847964
19.

First-line triple therapy with levofloxacin for Helicobacter pylori eradication.

Gisbert JP, Fernández-Bermejo M, Molina-Infante J, Pérez-Gallardo B, Prieto-Bermejo AB, Mateos-Rodríguez JM, Robledo-Andrés P, González-García G.

Aliment Pharmacol Ther. 2007 Aug 1;26(3):495-500.

20.

Impact of quadruple regimen of clarithromycin added to metronidazole-containing triple therapy against Helicobacter pylori infection following clarithromycin-containing triple-therapy failure.

Ueki N, Miyake K, Kusunoki M, Shindo T, Kawagoe T, Futagami S, Tsukui T, Inagaki H, Sakamoto C.

Helicobacter. 2009 Apr;14(2):91-9. doi: 10.1111/j.1523-5378.2009.00664.x.

PMID:
19298336

Supplemental Content

Support Center